v3.26.1
Revenue from contracts with customers and trade receivables (Details 3)
₨ in Millions, $ in Millions
 12 Months Ended
Mar. 31, 2026
INR (₨)
Mar. 31, 2026
USD ($)
 [1],[2]
Mar. 31, 2025
INR (₨)
Mar. 31, 2025
USD ($)
 [1],[2]
Mar. 31, 2024
USD ($)
 [1],[2]
Statements [Line Items]          
Provision used during the year ₨ (4,816)        
Effect of changes in foreign exchange rates 484        
Refund Liability [Member]          
Statements [Line Items]          
Balance at the beginning of the year 5,297   ₨ 4,579    
Provision made during the year, net of reversals 5,666   4,784    
Provision used during the year (4,816) $ (33) (4,129) $ (27) $ (21)
Effect of changes in foreign exchange rates 467   63    
Balance at the closing of the year 6,614   5,297    
Current 6,614   5,297    
Non-current ₨ 0   ₨ 0    
[1] Currently, the Company does not separately track the credits and payments, in each case to the extent relating to prior years for chargebacks, rebates, Medicaid payments or refund liability.
[2] The Company’s overall provision for refund liability as of March 31, 2026 relating to the Company’s North America Generics business was U.S.$47, compared to a liability of U.S.$42 as of March 31, 2025. The refund liability created for new product launches and volume growth, were off-set by the reductions in the contract prices and by product mix changes.